Nitrofurantoin: An alternative therapy for uncomplicated cystitis in the era of antimicrobial resistance

Journal of Clinical and Diagnostic Research

Volumn 5, Issue 5, 2011, Pages 964-966

  Asha Pai, K B ^a   Rai, Rekha ^a   Sanjeev, H ^a   Karnaker, Vimal Kumar ^a   Krishna Prasad, M S ^a  

^a NITTE DEEMED TO BE UNIVERSITY   (India)

Author keywords

Antimicrobial resistance; Escherichia coli; Nitrofurantoin; Uncomplicated cystitis

Indexed keywords

AMIKACIN; CIPROFLOXACIN; COTRIMOXAZOLE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; NITROFURANTOIN; NORFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIURIA; CONTROLLED STUDY; CYSTITIS; DISK DIFFUSION; DRUG CHOICE; ESCHERICHIA COLI; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; SPECIES COMPARISON; URINALYSIS;

ESCHERICHIA COLI;

EID: 80054725363     PISSN: None     EISSN: 0973709X     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Kashanian J, Hakimian P, Blute M, Wong J, Khanna H, Wise G et al. Nitrofurantoin: the return of an old friend in the wake of growing resistance. BJU International 2008; 102: 1634-1637.
2. Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement M 100-S17. Approved standard. Wayne, PA, USA, 2007.
3. Waren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE, et al. Guidelines for the antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Disease Society of America (IDSA). Clin Infect Dis 1999; 29: 745-58.
4. Randrianirina F, Soares JL, Fran J, Carod C, Ratsima E. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in Antananarivo, Madagascar. J Antimicrob Chemother 2007; 59: 309-312.
5. Yilmaz N, Agus N, Yurtsever SG, Pullukcu H, Gulay, Coskuner A et al. Prevalence of antimicrobial susceptibility of Escherichia coli in out patient urinary isolates in Izmir, Turkey. Med Sci Monit 2009; 15(1):61-65.
6. Sire JM, Nabeth P, Perrier-Gros-Claude JD, Bahsoun I, Siby T, Macondo EA, et al. Antimicrobial resistance in outpatient Escherichia coli urinary isolates in Dakar, Senegal. J Infect Developing Countries 2007; 1(3): 263-68.
7. Thankiwale SS, Jalgaonkar SV, Ahamad S, Hassani U. Evaluation of extended spectrum beta lactamase in urinary isolates. Indian J Med Res 2004; 120: 553-56.
8. Stratchounski LS, Rafalski VV. Antimicrobial susceptibility of the pathogens which were isolated from adult patients with uncomplicated, community-acquired urinary tract infections in the Russian federation: two multicentre studies, UTIAP-1 and UTIAP-2. Int J Antimicrob Agents 2006; 28(1):S4-S9.
9. Gobernado M, Valdes L, Alos JI, Garcia-Rey C, Dal-Re R, Garcia-de- Lomas J, et al. Antimicrobial susceptibility of clinical Escherichia coli isolates from uncomplicated cystitis in women over a 1-year period in Spain. Rev Esp Quimioter 2007; 20:68-76.
10. Karaca Y, Coplu N, Gozalan A. Cotrimoxazole and quinolones resistance in Escherichia coli which was isolated from urinary tract infections over the last 10 years. Int J Antimicrobial Agents 2005; 26: 75-77.
11. Frencesco MA, Ravizalla G, Peroni L. Urinary tract infections in Brescia, Italy: the aetiology of the uropathogens and the antimicrobial resistance of the common uropathogens. Med Sci Monit, 2007: 13(6): BRI 36-44.
12. Zhanel GG. Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaboration Alliance (NAUTICA). Int J Antimicrob Agents 2005; 26:380-388.
13. Tripati KD. Aminoglycosides. In: Tripati M, Tripati V editors. Essentials of medical pharmacology. New Delhi: Jaypee brothers, 1999; p.730-738.
14. Akram M, Shahid M, Khan AU. The aetiology and the antibiotic resistance patterns of community-acquired urinary tract infections in the JNMC Hospital Aligarh, India. Ann Clinl Microbiol Antimicrob 2007; 6:4.
15. Narayanaswamy A, Mallika M. The prevalence and susceptibility of extended spectrum beta-lactamases in the urinary isolates of Escherichia coli in a tertiary care hospital in Chennai, South India. Internet Journal of Medical Update 2011; 6(1):39-43.
16. Mehrgan H, Rahbar M. Prevalence of extended-spectrum betalactamase- producing Escherichia coli in a tertiary care hospital in Tehran, Iran. Int J Antimicrob Agents 2008; 31(2):147-151.
17. Gupta K, Sahm DF, Mayfield D, Stamm WE. Antimicrobial resistance among uropathogens that cause community acquired urinary tract infections in women: A nationwide analysis. Clin Infect Dis 2001; 33:89-94.
18. Eshwarappa M, Dosegowda R, Aprameya VI, Khan MW, Kumar SP, Kempegowda P, et al. The clinico-microbiological profile of urinary tract infections in south India. Indian J Neprol 2011; 21: 30-36.
19. Behera B, Mathur P, Das A, Kapil A. The ertapenem susceptibility of extended spectrum β-lactamase-producing enterobacteriaceae at a tertiary care centre in India. Singapore Med J 2009; 50(6):628-32.
20. Kothari A, Sagar V. Antibiotic resistance in pathogens which cause community-acquired urinary tract infections in India: a multicenter study. J Infect Developing Countries 2008; 2(5):354-58.
21. Mody RM, Erwin DP, Summers AM, Carrero HA, Selby SB, Ewell AJ, Moran KA. Ertapenem susceptibility of extended spectrum betalactamase- producing organisms. Annals of Clinical Microbiology and Antimicrobials 2007; 6: 1-5.
22. Gupta K, Hooton TM, Roberts PL, Stamm WE. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. Arch Intern Med. 2007; 167(20):2207-12.
23. Karlowsky JA, et al. Thornsberry C, Jones ME, Sahm DF. Susceptibiliy of antimicrobial resistant urinary Escherichia coli to fluoroquinolones and nitrofurantoin. Clin Infect Dis 2003; 36:183-7.
24. Garau J. Other antimicrobials of interest in the era of extended spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect 2008; 14(Suppl 1): 198-202.